Related Experiment Video
Updated: Jul 11, 2025
09:32
Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
Published on: September 10, 2017
11.0K
P53 IHC Result as a Prognostic Tool in MDS
Alireza Rezvani1, Ahmad Monabati2, Zahra Kargar3
1Department of Hematology, Medical Oncology and Stem Cell Transplantation, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Iranian Journal of Pathology
|November 9, 2023
Summary
Myelodysplastic syndrome (MDS) prognosis is improved by assessing p53 expression. This immunohistochemical analysis aids in predicting survival and guiding treatment decisions for MDS patients.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Current prognostic scoring systems like the Revised International Prognostic Scoring System (IPSS-R) may not fully capture prognosis in all MDS patients.
- Genetic factors are increasingly recognized as crucial for understanding MDS outcomes.
Purpose of the Study:
- To evaluate the prognostic value of p53 expression in myelodysplastic syndrome (MDS) patients.
- To determine if p53 immunohistochemistry (IHC) can improve survival prediction beyond existing scoring systems.
- To explore the utility of p53 IHC as an adjunct diagnostic tool in MDS.
Main Methods:
- Cross-sectional study of adult MDS patients from March 2015 to March 2020.
- Retrospective data collection from medical records.
- Immunohistochemical (IHC) staining for p53 on bone marrow biopsies.
Main Results:
- p53 expression was observed in 77.4% (65/84) of MDS patients.
- Patients with p53 expression exhibited shorter median survival compared to those without.
- High p53 expression was noted in low-risk IPSS-R patients who experienced mortality.
Conclusions:
- p53 expression assessed by IHC is a significant indicator of survival in MDS.
- Immunohistochemical analysis of p53 serves as a valuable prognostic tool for MDS.
- p53 IHC should be considered as an adjunct test for therapeutic decision-making in MDS.
